USE OF FASL OR FASL TRANSFECTED CD4+/FASL-/TH1-CELL LINES FOR THE TREATMENT OF TH1/TH2 DISEASES

摘要

Disclosed are the use of FasL as active pharmacological component in thetreatment of TH1/TH2 diseases, compositions containing FasL and one or morecytokines, specially interferon-.gamma., the use of a composition according toclaims 11 and 12 for the treatment of TH1/TH2 diseases, the use of autologousCd4+/FasL-/TH1 cell lines of the patient, transfected with the FasL genesequence or with physiologically active fragments of the FasL gene sequencefor the treatment of TH1/TH2 diseases.